GC-MS Analysis and In Vivo and Ex Vivo Antidiarrheal and Antispasmodic Effects of the Methanolic Extract of
Acacia
Animals
Antidiarrheals
/ chemistry
Diarrhea
/ drug therapy
Gas Chromatography-Mass Spectrometry
Gastrointestinal Agents
/ pharmacology
Jejunum
Methanol
/ pharmacology
Mice
Papaverine
/ pharmacology
Parasympatholytics
/ chemistry
Phosphoric Diester Hydrolases
/ pharmacology
Plant Extracts
/ pharmacology
Polyphenols
/ pharmacology
Rats
A. nilotica
Ca++ channel blocker
GC-MC
antispasmodic
phosphodiesterase inhibitor
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
24 Mar 2022
24 Mar 2022
Historique:
received:
03
02
2022
revised:
18
03
2022
accepted:
22
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
14
4
2022
Statut:
epublish
Résumé
This present study evaluated and rationalized the medicinal use of the fruit part of Acacia nilotica methanolic extract. The phytochemicals were detected using gas chromatography−mass spectrometry (GC−MS) while the in vivo antidiarrheal test was done using Swiss albino mice. To determine the details of the mechanism(s) involved in the antispasmodic effect, isolated rat ileum was chosen using different ex vivo assays by maintaining a physiological environment. GC−MS results showed that A. nilotica contained pyrogallol as the major polyphenol present (64.04%) in addition to polysaccharides, polyphenol, amino acid, steroids, fatty acid esters, and triterpenoids. In the antidiarrheal experiment, A. nilotica inhibited diarrheal episodes in mice significantly (p < 0.05) by 40% protection of mice at 200 mg/kg, while 80% protection was observed at 400 mg/kg by the orally administered extract. The highest antidiarrheal effect was observed with loperamide (p < 0.01), used as a control drug. In the ex vivo experiments, A. nilotica inhibited completely in increasing concentrations (0.3 to 10 mg/mL) the carbachol (CCh; 1 µM) and high K+ (80 mM)-evoked spasms in ileum tissues at equal potencies (p > 0.05), similar to papaverine, a dual inhibitor of the phosphodiesterase enzyme (PDE) and Ca++ channels. The dual inhibitory-like effects of A. nilotica on PDE and Ca++ were further validated when A. nilotica extract (1 and 3 mg/mL)-pre-incubated ileum tissues potentiated and shifted isoprenaline relaxation curves towards lower doses (leftward), similar to papaverine, thus confirming the PDE inhibitory-like mechanism whereas its CCB-like effect of the extract was confirmed at 3 and 5 mg/mL by non-specific inhibition of CaCl2-mediated concentration response curves towards the right with suppression of the maximum peaks, similar to verapamil, used as standard CCB. Thus, this study characterized the chemical composition and provides mechanistic support for medicinal use of A. nilotica in diarrheal and hyperactive gut motility disorders.
Identifiants
pubmed: 35408506
pii: molecules27072107
doi: 10.3390/molecules27072107
pmc: PMC9000243
pii:
doi:
Substances chimiques
Antidiarrheals
0
Gastrointestinal Agents
0
Parasympatholytics
0
Plant Extracts
0
Polyphenols
0
Papaverine
DAA13NKG2Q
Phosphoric Diester Hydrolases
EC 3.1.4.-
Methanol
Y4S76JWI15
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deputyship for Research & Innovation, Ministry of Education in Saudi Arabia
ID : IF-PSAU-2021/03/18673
Références
Int J Antimicrob Agents. 2000 Feb;14(1):65-9
pubmed: 10717503
Phytother Res. 2015 Aug;29(8):1211-8
pubmed: 25975350
Indian J Pediatr. 2011 Feb;78(2):165-70
pubmed: 20924718
J Ethnobiol Ethnomed. 2006 Mar 20;2:14
pubmed: 16545146
Aliment Pharmacol Ther. 2004 Dec;20(11-12):1253-69
pubmed: 15606387
Br J Pharmacol. 2006 Nov;149(6):611-23
pubmed: 17016496
Pharmacol Rev. 1986 Dec;38(4):321-416
pubmed: 2432624
Phytomedicine. 2012 Sep 15;19(12):1059-67
pubmed: 22884305
Ann Intern Med. 2000 Jul 18;133(2):136-47
pubmed: 10896640
Annu Rev Pharmacol Toxicol. 1977;17:149-66
pubmed: 326161
J Clin Microbiol. 2004 Mar;42(3):1203-6
pubmed: 15004076
Dig Dis Sci. 2010 Jan;55(1):145-9
pubmed: 19169820
Eur J Pharmacol. 1978 Dec 1;52(3-4):313-22
pubmed: 729641
Molecules. 2021 Apr 27;26(9):
pubmed: 33925478
Mol Aspects Med. 2006 Feb;27(1):1-93
pubmed: 16105678
J Pharmacol Sci. 2005 Jul;98(3):275-82
pubmed: 15988126
Br J Pharmacol. 2006 Jan;147 Suppl 1:S252-7
pubmed: 16402111
Phytother Res. 2013 Jul;27(7):1086-94
pubmed: 23007892
Neuropharmacology. 2011 Dec;61(8):1275-81
pubmed: 21816164
J Pharmacol Exp Ther. 1977 Jun;201(3):662-8
pubmed: 864602
Int J Clin Pract. 2006 Jan;60(1):57-63
pubmed: 16409429
J Ethnopharmacol. 2012 Nov 21;144(2):395-401
pubmed: 23026304
J AOAC Int. 2020 Jun 1;103(3):659-668
pubmed: 31619315
Fundam Clin Pharmacol. 2005 Dec;19(6):695-705
pubmed: 16313282
Molecules. 2020 Feb 24;25(4):
pubmed: 32102361
Phytother Res. 1999 Dec;13(8):665-9
pubmed: 10594935
Br J Pharmacol. 1997 Jun;121(3):375-80
pubmed: 9179376
Phytother Res. 2014 Sep;28(9):1349-58
pubmed: 24610729
J Ethnopharmacol. 2015 Jun 20;168:182-90
pubmed: 25861952
Jpn J Pharmacol. 1962 Dec;12:137-45
pubmed: 13957106
Br J Pharmacol. 1986 May;88(1):103-11
pubmed: 3708211
Phytother Res. 1999 Sep;13(6):474-8
pubmed: 10479756
Evid Based Complement Alternat Med. 2014;2014:525340
pubmed: 24872833